PharmaMar (MSE: PHM) today announced the signing of a licensing agreement with Key Oncologics (Pty) Ltd. for the commercialization and distribution of Zepzelca (lurbinectedin), its marine-derived antitumor for small cell lung cancer (CPCP), in South Africa, Namibia, Zimbabwe, Mozambique, Swaziland, Lesotho and Botswana.

PharmaMar will retain exclusive production rights, while Key Oncologics (Pty) Ltd. will apply for marketing approval and will have the right to exclusively market the product. In this way, the commercial relationship between both companies is expanded, which already in 2020 closed a commercial alliance for the sale and distribution of Yondelis in South Africa, Namibia and Botswana.

With this agreement, there are now 10 strategic alliances signed by PharmaMar with its partners around the world for the commercialization of lurbinectedin. In the words of Luis Mora, general director of the Oncology, Virology and Genetic Identification Business Units: 'This new agreement expands the possibilities for patients to access innovative medicines. At PharmaMar, with a vocation as a global company, we work through alliances with strategic partners to make our therapies available to doctors and patients.'

Magriet de Wet, CEO of Key Oncologics (Pty) Ltd, said: 'We are very pleased to extend our collaboration agreement with PharmaMar, a company that shares our values. We are excited about the opportunity that Zepzelca represents for Key Oncologics (Pty). Ltd. and for SCLC patients in South Africa, Namibia, Zimbabwe, Mozambique, Swaziland, Lesotho and Botswana. This milestone provides an exciting prospect to further expand our product portfolio and strengthen our position as leaders in the oncology market in the aforementioned territories. We hope to continue collaborating for many years.'

Lurbinectedin is approved in 13 countries worldwide for the treatment of adult SCLC patients with disease progression during or after platinum-based chemotherapy. SCLC accounts for up to 15% of all lung cancer cases.

Contact:

Tel: +34 91 846 6000

Fax: 91 846 6001

Email: pharmamar@pharmamar.com

(C) 2023 Electronic News Publishing, source ENP Newswire